Showing 381-390 of 447 results for "".
Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21709/Lead Psoriasis Patients Along the Path to Clearance
https://practicaldermatology.com/topics/psoriasis/PD0209_01-php/22873/With so many effective therapies now available, dermatologists must be prepared to guide their patients to the right treatment for their specific presentation.Diversity and Inclusion in Dermatology: The Impact of Systemic Racism in Dermatology and Opportunities for Change
https://practicaldermatology.com/issues/supplements/diversity-and-inclusion-in-dermatology-the-impact-of-systemic-racism-in-dermatology-and-opportunities-for-change/23474/Mechanism of Action Matters: A Review of New and Emerging Biologics
https://practicaldermatology.com/issues/supplements/mechanism-of-action-matters-a-review-of-new-and-emerging-biologics/23178/2020 In Review
https://practicaldermatology.com/topics/skin-cancer-photoprotection/2020-in-review/23402/Top trends and developments from the yearRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-33/23690/MOC Sparks Anger, Frustration in Physician Community
https://practicaldermatology.com/topics/practice-management/moc-sparks-anger-frustration-in-physician-community/20898/Anti-MOC advocates wonder why they cannot get a seat at the table to discuss changing the system.Diversity and Equity in Dermatology
https://practicaldermatology.com/topics/practice-management/diversity-and-equity-in-dermatology/23456/2019 In Review
https://practicaldermatology.com/topics/practice-management/2019-in-review/23168/A look back at approvals, data, and industry developments of the year.- Nomir Medical Submits 510(k) Application to FDA for Onychomycosishttps://practicaldermatology.com/news/20120911-nomir_medical_announces_510k_application_to_fda_for_onychomycosis/2459742/Nomir Medical Technologies, Inc. submitted a 510(k) application to the US Food and Drug Administration (FDA) for the indication of temporary increase of clear nail in patients with onychomycosis (toenail fungus). This 510(k) submission to FDA